The following SWOT synthesises the analysis into the factors most material to lenders and equity investors.
|
STRENGTHS
|
- Vast, under-served, growing demand
- Integrated one-stop eye-care model
- National standardised, tech-enabled platform
- Diversified across surgery, optical & screening
- Strong impact & medical-aid alignment
|
|
|
|
WEAKNESSES
|
- Acute dependence on scarce ophthalmologists
- Capital-intensive, equipment-heavy build
- Loss-making, cash-consumptive early rollout
- Ambitious surgical-throughput targets
- New brand across nine provinces at once
|
|
|
OPPORTUNITIES
|
- Cataract backlog & unmet WHO targets
- Diabetic-retinopathy screening at scale
- AI & tele-ophthalmology leverage
- Corporate, mining & government contracts
- Regional (SADC) expansion later
|
|
|
|
THREATS
|
- Ophthalmologist recruitment shortfall
- NHI & medical-aid tariff/policy change
- Rollout delays & cost overruns
- Slower-than-planned clinic ramp
- Equipment / forex & financing cost
|
|